Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella
Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019
VANCOUVER, B.C. and SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, is pleased to announce that the Company has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop a cannabinoid-based product for the treatment of glioblastoma multiform and brain metastases. The program, developed in the lab of renowned cannabis researcher Dr. Nephi Stella, founder and co-director of the UW Center for Cannabis Research, includes a lead therapeutic, ST-403. Pascal plans to begin human clinical studies of ST-403 in 2019.
“I believe the ST-403 program has great potential to help patients diagnosed with glioblastoma, brain metastases and other devastating cancers,” said Dr. Stella. “I’m excited to have Pascal advancing this promising program and, furthermore, I am honoured to help with the future development of Pascal’s broad immune-oncology program, as I believe cannabinoid-based compounds have great potential when combined with checkpoint inhibitors.”
Dr. Stella began developing ST compounds based on scientific reports that cannabis-derived compounds may have benefit for glioblastoma, and he collaborated with Associate Professor Dr. Philippe Diaz of the University of Montana (UM) Department of Biomedical & Pharmaceutical Sciences. CoMotion, UW’s collaborative innovation hub, supported the work through two CoMotion Innovation Gap Fund grants and letters of support for a variety of other funding. CoMotion and joint owner (University of Montana), worked together in order to secure exclusive rights to license the compound to the company.
ST compounds utilize a unique mechanism of action to kill cancer cells that may prove synergistic when used in combination with chemotherapeutics. In a preclinical model of glioblastoma, mice are treated with radiation and temozolomide, which is the standard of care for human patients; ST compounds synergize with these treatments to reduce tumour size and extend life. These compounds also demonstrated a favourable safety profile. These results support Pascal’s plans to begin clinical trials with ST-403 in 2019.
“ST-403 is a very promising therapeutic candidate that is an ideal fit with our cannabinoid immune activation program that we announced in February,” said Dr. Patrick Gray, CEO of Pascal. “Both programs have great potential in treating cancer, and we are fortunate to have access to and support from Dr. Stella to help facilitate the advancement of this great science into meaningful therapeutics for cancer.”
Pascal’s exclusive license agreement with the UW covers the ST-403 program, all related compounds, and a strong patent portfolio. If ST-403 has demonstrated benefit for glioblastoma patients, its commercial potential is significant: Temozolomide is now off patent protection, but previously had sales over $1B per year.
ST-403 is a mitosis inhibitor that blocks cell division. Drugs of this class disrupt microtubules, which are the structures that pull chromosomes apart during cell division. There are several mitotic inhibitors approved for cancer treatment, including paclitaxel and vinblastine, and they have substantial benefit on solid tumours when combined with other chemotherapeutics. However, unlike ST-403, none of these agents cross the blood brain barrier and therefore have no activity on glioblastoma or other brain cancers.
Glioblastoma multiforme is a devastating disease for patients due to the high rate of recurrence, limited treatment options and aggressive nature of the disease. According to the National Brain Tumor Society, glioblastoma strikes about 15,000 patients each year in North America with a median survival rate of 12 to 17 months. Therapies to treat glioblastoma are limited to surgery, radiation and chemotherapy, and more recently tumour treating fields. The only chemotherapeutic approved for glioblastoma is temozolomide, which was developed over 50 years ago and extends survival by only two months. Temozolomide kills tumour cells by causing DNA damage, a mechanism that is different from ST compounds.
About Pascal Biosciences Inc.
Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. For more information, visit www.pascalbiosciences.com.
About the University of Washington and CoMotion
Recently ranked by Reuters as the #1 most innovative public university in the U.S., the University of Washington (UW) is a leading recipient of federal funding research, producing innovations that have the power to change the world—from biofuel alternatives, to more effective treatments for Alzheimer’s disease and brain cancer, to purification technology for drinking water in the developing world.
CoMotion at the UW is the collaborative innovation hub dedicated to expanding the economic and societal impact of the UW community. By developing and connecting to local and global innovation ecosystems, CoMotion helps innovators achieve the greatest impact from their ideas and discoveries.
About the University of Montana
The University of Montana receives approximately $100M in research funding annually in areas intended for impactful societal change. Areas of national recognition include ecology, the environment, wildlife biology, and health and medicine.
On Behalf of the Board of Directors
Dr. Patrick W. Gray, President & CEO
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”